Allscripts was Downgraded to a Hold Rating at Deutsche BankBy Ryan Adsit
According to TipRanks.com, Hill is a 1-star analyst with an average return of -3.5% and a 40.5% success rate. Hill covers the Healthcare sector, focusing on stocks such as Quintiles Transnational, Charles River Labs , and Express Scripts.
Currently, the analyst consensus on Allscripts is Moderate Buy and the average price target is $16.50, representing a 59.7% upside.
In a report issued on November 4, Oppenheimer also reiterated a Hold rating on the stock.
Based on Allscripts’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $392 million and GAAP net loss of $10.19 million. In comparison, last year the company earned revenue of $354 million and had a GAAP net loss of $5.24 million.
Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is negative on the stock. Most recently, in August 2015, James Hewitt, the SVP Development of MDRX sold 70,000 shares for a total of $991,200.
Allscripts Healthcare Solutions, Inc. engages in the provision of clinical, financial, connectivity, information solutions, and related professional services. It operates through Clinical and Financial Solutions, and Population Health segments. The Clinical and Financial Solutions segment involves in the sale of clinical software applications and financial and information solutions. The Population Health segment offers health management and coordinated care solutions. The company was founded in 1986 and is headquartered in Chicago, IL.